650
Views
3
CrossRef citations to date
0
Altmetric
Case Reports

Pericardial and Pleural Effusion with Valproic Acid use in a Patient with Bipolar Disorder

İki uçlu bozukluğu olan bir hastada valporik asit nedenli perikardiyal ve plevral efüzyon

, M.D., , M.D., , M.D. &
Pages 387-390 | Received 05 Dec 2013, Accepted 02 Sep 2014, Published online: 08 Nov 2016
 

ABSTRACT

Valproic acid is a widely used drug in various medical situations and settings. The occurrence of pleural effusion due to the use of valproic acid is very rarely encountered. Here, we present a case diagnosed with bipolar disorder, who had used valproic acid for a year. Pericardial and pleural effusion was determined in the case during the treatment. To the best of our knowledge, the presented case is the first to report the concurrent development of exudative pericardial and pleural effusion arising from the use of valproic acid.

ÖZET

Valproik asit, birçok nörolojik ve psikiyatrik bozukluğun tedavisinde kullanılan bir ilaçtır. Valproik asit kullanımına bağlı olarak nadiren plevral efüzyon oluşumu görülebilmektedir. İki uçlu bozukluk tanısıyla bir yıldır valproik asit kullanan bir hasta sunmaktayız. Olguda tedavi sırasında plevral ve perikardiyal efüzyon saptanmıştır. Bizim bilgimize göre, valproik asit kullanımı ile ilişkili olarak eş zamanlı perikardiyal ve plevral efüzyon gelişmesinin bildirildiği ilk olgudur.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.